dRx Capital: Novartis' digital health venture fund, investing in tech transforming healthcare & optimizing pharma practices.
Location
Basel, Basel-Stadt, CH
Founded
2015
dRx Capital, founded in 2015, is Novartis' Digital Health Venture Fund focused on investing in entrepreneurs who are transforming healthcare through data and digital technology. The firm targets technology platforms that enhance access to healthcare and reimagine medical practices, with a particular emphasis on AI & ML, big data, R&D optimization, patient care, and the pharma supply chain. dRx Capital typically invests in Series A, B, and C rounds, with occasional pre-seed and post-IPO equity investments.
Notable portfolio companies include Freenome, H1, Pear Therapeutics, and Omada Health. The firm is led by key decision-makers affiliated with Novartis, leveraging their extensive expertise in the pharmaceutical industry. dRx Capital's investment philosophy centers on driving operational efficiency and transforming current healthcare practices. They offer unique value-add services such as strategic guidance and access to Novartis' vast resources and networks, providing significant support to their portfolio companies.
dRx Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages